Fmr LLC Purchases 428,335 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Fmr LLC lifted its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 7,098.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 434,369 shares of the biopharmaceutical company’s stock after acquiring an additional 428,335 shares during the period. Fmr LLC owned approximately 0.28% of Ocular Therapeutix worth $3,779,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in OCUL. Mirae Asset Global Investments Co. Ltd. increased its holdings in Ocular Therapeutix by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 1,015 shares in the last quarter. Essex Investment Management Co. LLC lifted its holdings in shares of Ocular Therapeutix by 0.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 443,677 shares of the biopharmaceutical company’s stock worth $3,860,000 after purchasing an additional 1,168 shares in the last quarter. Amalgamated Bank grew its position in Ocular Therapeutix by 37.9% in the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,481 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Ocular Therapeutix by 36.9% in the 2nd quarter. Victory Capital Management Inc. now owns 17,403 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 4,695 shares during the last quarter. Finally, Atlas Capital Advisors LLC purchased a new position in shares of Ocular Therapeutix during the second quarter valued at approximately $34,000. 59.21% of the stock is owned by institutional investors and hedge funds.

Ocular Therapeutix Stock Down 2.2 %

Shares of NASDAQ OCUL opened at $8.69 on Friday. Ocular Therapeutix, Inc. has a one year low of $3.24 and a one year high of $11.77. The business’s fifty day moving average price is $10.06 and its 200-day moving average price is $8.48. The stock has a market capitalization of $1.37 billion, a PE ratio of -6.58 and a beta of 1.19. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Insiders Place Their Bets

In related news, insider Jeffrey S. Heier sold 2,948 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $9.01, for a total transaction of $26,561.48. Following the completion of the transaction, the insider now owns 269,059 shares of the company’s stock, valued at approximately $2,424,221.59. The trade was a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.50% of the company’s stock.

Wall Street Analyst Weigh In

OCUL has been the subject of a number of analyst reports. Scotiabank began coverage on Ocular Therapeutix in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Ocular Therapeutix has an average rating of “Moderate Buy” and an average price target of $16.71.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.